| Trial ID: | L3430 |
| Source ID: | NCT00715663
|
| Associated Drug: |
Biphasic Insulin Aspart 30
|
| Title: |
Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2|Delivery Systems
|
| Interventions: |
DRUG: biphasic insulin aspart 30
|
| Outcome Measures: |
Primary: Change in HbA1c, after 12 weeks of therapy|Change in post-prandial glucose (PPG), after 12 weeks of therapy|Change in fasting plasma glucose (FPG), after 12 weeks of therapy|Change in prandial glucose increment (PGI), after 12 weeks of therapy|Incidence of hypoglycaemia and other adverse drug reaction, after 12 weeks of therapy|Patient and doctor's convenience, after 12 weeks of therapy | Secondary: Response of different patient profiles to NovoMix 30 therapy and patient profiles considered eligible for insulin treatment in physicians' routine clinical practice, For the duration of the study|Patient satisfaction on devices, after 12 weeks of treatment
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1584
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2007-02
|
| Completion Date: |
2007-12
|
| Results First Posted: |
|
| Last Update Posted: |
2016-12-13
|
| Locations: |
Novo Nordisk Investigational Site, Jakarta, 12520, Indonesia
|
| URL: |
https://clinicaltrials.gov/show/NCT00715663
|
